ARCHIVES

Cancer Organizations Continue Reform Lobbying: Target Issue Are Off-Label Drugs, Clinical Trials

This article is from The Cancer Letter archive.

Vol. 19 No. 13 | March 26, 1993

Download PDF Visit The Full Archive

Related Articles

NCI National Lab’s Budget to Grow Over Its $299.2 Million FY2013 Level

February 28, 2014

How Cancer Control Grants, Contracts Distributed By States

October 13, 1978

UICC Seeks Nominations for Mucio Athayde Prize.

January 7, 2000

GPC Biotech’s Satraplatin Fails To Extend Survival In Hormone-Refractory Prostate Cancer.

November 2, 2007

Two Phase II Trials Display Ramucirumab Potential Efficacy

October 26, 2012

Conversation with The Cancer Letter: Einhorn: “I Still Harbor Hope For Similar Success Stories”

October 24, 2014